College of Psychiatric and Neurologic Pharmacists

At the completion of the training workshop, participants will be able to intervene with all tobacco users, including patients/clients who are not yet considering quitting, by practicing skills as recommended by the U.S. Public Health Service Clinical Practice Guideline, Treating Tobacco Use and Dependence: 2008 Update

1. Describe the purpose of the Basic Tobacco Intervention Skills for Medical and Allied Health Professionals and the 2008 update to Treating Tobacco Use and Dependence.
2. Recognize the clinical issues related to tobacco use in patients with mental illness and substance abuse disorders.
3. Describe tobacco basics that includes the biological, psychological, and sociocultural components of tobacco dependence.
4. Identify the “Five A’s” and give a brief explanation of each with using the “Readiness to Change Model” and “Brief Intervention Flow Chart”
5. Conduct an integrated, stage-specific Five A Model brief intervention for tobacco cessation.
6. Recommend pharmacologic therapies for smoking cessation (i.e., nicotine replacement therapy, bupropion, varenicline, and off-label pharmacologic therapies) based on the cost of therapy, patient-specific disease states, adverse side effects, efficacy, and adherence factors.
7. Integrate tobacco cessation treatment and smoke-free environments into mental health care settings.
8. Recognize the importance of pharmacist’s interventions and teaching other health care professionals about intervention techniques for tobacco cessation.
9. Demonstrate knowledge of basic tobacco interventions and program objectives.

1. Identify risk factors for suicidal behavior and ideation in youth that are associated with depression and antidepressant treatment.
2. Compare the clinical outcomes related to suicidality and suicide rates from recent antidepressant trials assessing the effectiveness of depression treatment in children, adolescents, and adults.
3. Explain the clinical impact on depression treatment and suicide rates before and after the introduction of FDA mandated suicidality warnings.
4. Design a treatment regimen with monitoring parameters for a child or adolescent with depression that includes nonpharmacologic therapy, antidepressants, and adjunctive agents.

1. Identify risk factors for suicidal behavior and ideation in youth that are associated with depression and antidepressant treatment.
2. Compare the clinical outcomes related to suicidality and suicide rates from recent antidepressant trials assessing the effectiveness of depression treatment in children, adolescents, and adults.
3. Explain the clinical impact on depression treatment and suicide rates before and after the introduction of FDA mandated suicidality warnings.
4. Design a treatment regimen with monitoring parameters for a child or adolescent with depression that includes nonpharmacologic therapy, antidepressants, and adjunctive agents.

1. Analyze clinical cases of children suffering from Attention-deficit/hyperactivity Disorder (ADHD) and subsequent symptom response to psychostimulants
2. Illustrate the contribution of structural neuroimaging to the neurobiology of ADHD
3. Explain the possible effects of psychostimulant treatment for ADHD on cortical structure.
4. Contrast the variable clinical outcomes of ADHD and identify the neurobiological correlates of differential outcome.

1. Recognize possible risk factors in post-stroke depression (PSD).
2. Assess symptoms of PSD
3. Assess the consequences of PSD on recovery and survival.
4. Evaluate available controlled trials with Selective Serotonin Reuptake Inhibitors for the treatment of PSD and the effect on recovery.
5. Identify the treatments which have been shown to be the most effective for PSD.

1. Compare and contrast the clinical presentation of attention-deficit hyperactivity disorder (ADHD) in children and adults.
2. Apply evidence-based strategies for screening, diagnosing, and monitoring of ADHD in adult patients.
3. Evaluate the efficacy and outcomes of traditional and new drug therapies for the management of adult patients with ADHD.

1. Explain the diagnostic criteria for fibromyalgia
2. Differentiate fibromyalgia from comorbidities and conditions with similar symptomatology
3. Identify nonpharmacologic treatments to help improve symptom control in fibromyalgia
4. Compare the safety and efficacy data for commonly used agents for treating fibromyalgia including antidepressants, pregabalin, and analgesics

1. Describe the various non-pharmacological treatment modalities and data supporting their use.
2. Explain the benefits of cognitive behavioral therapy in schizophrenia.
3. Describe the systematic use of environmental supports to bypass cognitive deficits and improve functional outcomes in schizophrenia.
4. Outline the resources available to implement evidence-based psychosocial rehabilitation techniques in community practice.

1. Describe and compare current European and U.S. guidelines for the treatment of bipolar disorder, noting key differences.
2. Examine the literature on the efficacy of lamotrigine for the acute and maintenance treatment of bipolar disorder.
3. Review the role of antidepressants in the treatment of bipolar depression.
4. Differentiate the effectiveness of the available second-generation antipsychotics in the treatment of bipolar disorder.
5. Analyze the current data available regarding the efficacy of carbamazepine for the acute and maintenance treatment of bipolar disorder.

1. Describe and compare current European and US guidelines for the treatment of bipolar disorder, noting key differences.
2. Examine the literature on the efficacy of lamotrigine for the acute and maintenance treatment of bipolar disorder.
3. Review the role of antidepressants in the treatment of bipolar depression.
4. Differentiate the effectiveness of the available second-generation antipsychotics in the treatment of bipolar disorder.
5. Analyze the current data available regarding the efficacy of carbamazepine for the acute and maintenance treatment of bipolar disorder.

1. Summarize common psychiatric comorbidities encountered in patients with alcohol dependence.
2. Examine treatment options for mood and anxiety disorders in patients with comorbid alcohol dependence.
3. Describe the impact of mood and anxiety disorders on outcomes in alcohol dependence treatment.
4. Evaluate treatments being tested for alcohol dependence in patients with mood and anxiety disorders.

1. Differentiate between the clinical presentation of dystonia and tremor disorders.
2. Discuss the benefits and limitations of treatments for dystonia and tremor disorders.
3. Outline a treatment approach for dystonia and tremor disorders

1. Identify delirium and its contributing causes.
2. Describe populations at risk of delirium and differentiate symptoms of anticholinergic delirium to symptoms of other deliriums and also to symptoms of dementia.
3. Distinguish the contribution of anticholinergic medications to delirium and also the exquisite sensitivity of anticholinergic medications in dementia patients.
4. Recognize the pharmacist’s role in assessing anticholinergic burden.
5. Describe management and preventive strategies for delirium and associated agitation.

1. Effective Manuscript/Research Grant Preparation/Submission and Funding Strategies
   
   Description:  This presentation/roundtable will provide helpful tips and tools to be used in manuscript preparation of study results which include approaches to drafting specific sections, targeting the right journal, tips in drafting a cover letter as well as responding to journal reviewer comments. Additionally, funding strategies as well as funding agencies will be discussed.
   
   Objectives: The purpose of this presentation/roundtable is to provide information in the following areas:
   1. Guidance in developing the key sections of the manuscript such as introduction, methods, results and discussion.
   2. Selection of appropriate target journals based on content, impact to practice/research.
   3. Manuscript submission and responding to reviewers comments.
   4. Selection of funding agencies and strategies for submission.
2. Developing Collaborative Practices/Reimbursement/Justification of Clinical Services for Pharmacists/CDTM
3. Residency Director Information Share
4. Didactic and clerkship site/experience development/innovative ideas
   
   Description: Discussion of innovative didactic and experiential learning experiences for students for psychiatric pharmacy topics. Discussion of team/problem-based learning in didactic courses as well as innovative preceptor arrangements/learning environments during APPEs would also occur. Other topics: streamlining psychiatric experiences, logistics/scheduling APPEs, etc.

1. Administrators, Directors, Managers
2. New Practitioners, Residents, Fellows
3. State Hospital Pharmacists
4. Canadian Pharmacists
5. Veterans Affairs Pharmacists

1. Acquire a basic understanding of genetic principles applicable to the study of pharmacogenomics.
2. Discuss results of recent pharmacogenomics studies and application to clinical practice.
3. Recognize the barriers in the process of translating data from pharamcogenomic studies to clinical practice.
4. Identify issues surrounding direct to consumer pharmacogenomic testing and the role of the FDA.

1. Identify five strategies to modify delivery of medications.
2. Explain what are the possible Pharmacodynamic advantages, which result from dosage formulation related changes in drug concentrations at their site of actions.
3. Identify future strategies for drug delivery and monitoring systems.
4. Summarize data available supporting (or not) the advantages of novel dosage forms.
5. Describe research strategies (and clinical approaches) to study the safety and efficacy of novel antipsychotic dosage forms.